65,437 trials
Hyperlipidemia
Primary: Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 — -0.8; -50.8 percent change — p=<0.001
Acute Respiratory Failure
Primary: Change of Respiratory Status Using the Modified Bronchiolitis Severity Score, in Children Using External Nasal Dilators as an Adjuvant to High Flow Nasal Cannula Oxygen…
Breast Health
Primary: Number of Participants With Acceptable Overall Clinical Image Quality — 14; 9 Participants
Anemia of Prematurity
Primary: Change in Superior Mesenteric Artery Blood Flow Velocity From Pre-to-post Feed in the Anemic and the Transfused States — 2.02; 5.91; 7.66; 14.99 cm/sec — p=0.571
Type 1 Diabetes
Primary: Average Blood Glucose (Co-primary Outcome) — 138 mg/dL
Gastroesophageal Reflux
Primary: Clinically Significant Reduction of PPI Usage at 12, 24, and 36 Month Follow-ups Compared to Baseline in Both Singly Treated and Retreated Patients. — 56.25; 45.45…
Colorectal Neoplasms
Primary: Progression-Free Survival (PFS) by Central Review Assessment — 1.38; 1.51 Months — p=<0.0001
Cigarette Smoking
Primary: Treatment Satisfaction — 17; 6; 16; 7 Participants
PICC · Central Venous Catheter · Central Line
Primary: Participants With Complications With Central Access Including Insertion — 14; 10 Participants — p=0.271
Dengue
Primary: Reactogenicity in Terms of Solicited Symptoms After Dose 1 of the Dengue Vaccine vs. Control Vaccine. — 3; 1; 11; 1 specified events
Pain · Nausea · Pruritus
Primary: Number of Participants With Naloxone Side Effects — 32 participants
Asthma
Primary: Airway Reactivity — 5.08; 2.37 mg/ml
Major Depressive Disorder
Primary: MADRS (Montgomery-Asberg Depression Rating Scale) Response Rate — 10; 11; 29; 5 Participants
Infections, Streptococcal
Primary: Number of Subjects With Grade 3 Solicited Local Symptoms — 0; 1; 0; 1 Participants
Metastatic Renal Cell Carcinoma (mRCC)
Primary: Percentage of Progression-free Patients by Month 6 — 8.3; 46.2 Percentage of participants